Trials with a site in La Jolla, California

Background: Genes are the basic units of heredity. When genes are changed, certain cells don t work like they should.

NCT02771236 · Official ClinicalTrials.gov record · National Eye Institute (NEI)

This is an umbrella study evaluating the how well it works and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages.

NCT03424005 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This is a prospective study for the long-term follow-up (LTFU) of safety and how well it works for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

NCT03435796 · Official ClinicalTrials.gov record · Celgene

This study will measure the long-term whether it is safe and how hard side effects are to live with of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomly assigned in WR42221.

NCT03683251 · Official ClinicalTrials.gov record · Hoffmann-La Roche

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants.

NCT03970447 · Official ClinicalTrials.gov record · Global Coalition for Adaptive Research

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR.

NCT04181060 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This is a Phase 1/2, open-label, non-randomly assigned, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

NCT04198766 · Official ClinicalTrials.gov record · Inhibrx Biosciences, Inc

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT04267848 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT04628767 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.

NCT04649242 · Official ClinicalTrials.gov record · Pfizer

This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

NCT04743141 · Official ClinicalTrials.gov record · Pfizer

In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites.

NCT04748809 · Official ClinicalTrials.gov record · University of California, San Diego

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.

NCT05137054 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The main objective of the study is to assess how well it works and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, neither you nor the study doctors know who gets the real treatment, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO.

NCT05263206 · Official ClinicalTrials.gov record · Sanofi

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE).

NCT05432804 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This study wants to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

NCT05498428 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

To study the effect of anti-inflammatory diet on clinical and biological outcomes in patients with knee osteoarthritis

NCT05559463 · Official ClinicalTrials.gov record · University of California, San Diego

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials.

NCT05564377 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

The Kesimpta Pregnancy Registry is an watch-and-measure (no experimental treatment required), exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

NCT05634967 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

This is a neither you nor the study doctors know who gets the real treatment, phase 2 study to evaluate safety and how well it works of rosuvastatin in comparison to dummy treatment (placebo) after 2 years in patients with compensated cirrhosis.

NCT05832229 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans.

NCT05987241 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

To assess the how well it works and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

NCT06023589 · Official ClinicalTrials.gov record · AstraZeneca

This is a phase III, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multi-center, global study to explore the how well it works and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

NCT06079671 · Official ClinicalTrials.gov record · AstraZeneca

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors.

NCT06126276 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

NCT06203600 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins and that may have spread from where they first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or to other places in the body (metastatic). Precision medicine is a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, or treat disease in a way that is tailored to the patient.

NCT06311214 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

The study will assess the how well it works and safety of 2 dose regimens of pegozafermin compared to dummy treatment (placebo) for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

NCT06318169 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study wants to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion).

NCT06400472 · Official ClinicalTrials.gov record · Eli Lilly and Company

The study will assess the how well it works and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .

NCT06419374 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study wants to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion).

NCT06465069 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the how well it works and safety of T-DXd with rilvegostomig or T-DXd this drug alone compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

NCT06467357 · Official ClinicalTrials.gov record · AstraZeneca

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT06498635 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs.

NCT06499285 · Official ClinicalTrials.gov record · Takeda

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).

NCT06541704 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss.

NCT06548542 · Official ClinicalTrials.gov record · AbbVie

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital.

NCT06578195 · Official ClinicalTrials.gov record · St. Joseph's Hospital and Medical Center, Phoenix

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT06580314 · Official ClinicalTrials.gov record · NRG Oncology

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study.

NCT06581432 · Official ClinicalTrials.gov record · Boehringer Ingelheim

The purpose of the dose escalation part of the study is to characterize the whether it is safe and how hard side effects are to live with of ALN-BCAT as this drug alone and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as this drug alone and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to measure the antitumor activity of ALN-BCAT as this drug alone and in combination with pembrolizumab; to characterize the whether it is safe and how hard side effects are to live with of ALN-BCAT as this drug alone and in combination with pembrolizumab.

NCT06600321 · Official ClinicalTrials.gov record · Alnylam Pharmaceuticals

This study wants to measure the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

NCT06617325 · Official ClinicalTrials.gov record · UCB Biopharma SRL

This study wants to assess the long-term whether it is safe and how hard side effects are to live with after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

NCT06635148 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT06661720 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments.

NCT06677060 · Official ClinicalTrials.gov record · AstraZeneca

This clinical trial is a prospective, multicenter, open-label, randomly assigned, actively controlled, parallel-group Phase 3 clinical trial to measure the how well it works, whether it is safe and how hard side effects are to live with of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

NCT06743126 · Official ClinicalTrials.gov record · Immatics US, Inc.

This is a Phase Ⅲ, randomly assigned, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the how well it works and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

NCT06764875 · Official ClinicalTrials.gov record · AstraZeneca

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer.

NCT06787612 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.

NCT06807437 · Official ClinicalTrials.gov record · SWOG Cancer Research Network

This clinical trial is designed to measure the how well it works and safety of T-DXd in combination with bevacizumab versus bevacizumab this drug alone as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

NCT06819007 · Official ClinicalTrials.gov record · Daiichi Sankyo

Polypharmacy and drug-drug interactions often limit statin optimization, including in a population of patients prescribed cytochrome P3A4 inhibitors such as, immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.

NCT06865885 · Official ClinicalTrials.gov record · University of California, San Diego

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors.

NCT06900595 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive).

NCT06901531 · Official ClinicalTrials.gov record · Astellas Pharma Global Development, Inc.

This is an open-label, multicenter, randomly assigned, phase 2 clinical study to measure the how well it works of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

NCT06955169 · Official ClinicalTrials.gov record · RTOG Foundation, Inc.

DESTINY-Endometrial01 will investigate the how well it works of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

NCT06989112 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to assess BMS-986500 as this drug alone in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

NCT06997029 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. this study wants to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).

NCT07007065 · Official ClinicalTrials.gov record · AbbVie

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the how well it works, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows: * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs.

NCT07007559 · Official ClinicalTrials.gov record · ALX Oncology Inc.

The purpose of the study is to measure the progression-free survival (PFS) of casdatifan versus dummy treatment (placebo) when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant this drug alone or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.

NCT07011719 · Official ClinicalTrials.gov record · Arcus Biosciences, Inc.

This study wants to measure the how well it works and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

NCT07011732 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds.

NCT07061977 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. this study wants to assess side effects and change in disease activity of telisotuzumab adizutecan as a this drug alone or in combination with osimertinib compared to standard of care (SOC).

NCT07155187 · Official ClinicalTrials.gov record · AbbVie

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.

NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.

NCT07174310 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study wants to characterize the how well it works and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

NCT07175285 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb).

NCT07216703 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

NCT07227246 · Official ClinicalTrials.gov record · Joseph Broderick, MD

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (major depression) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a dummy treatment (placebo) (a look-alike capsule with no medicine) to reduce symptoms of depression?

NCT07284667 · Official ClinicalTrials.gov record · ACADIA Pharmaceuticals Inc.

The primary objective of this trial is to measure the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

NCT07288138 · Official ClinicalTrials.gov record · Eccogene

The primary objective of this dose-finding study is to measure the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.

NCT07290062 · Official ClinicalTrials.gov record · Insmed Gene Therapy LLC

TROPION-Lung17 will measure the how well it works and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

NCT07291037 · Official ClinicalTrials.gov record · AstraZeneca

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible.

NCT07318558 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM?

NCT07326566 · Official ClinicalTrials.gov record · Black Diamond Therapeutics, Inc.

This first-time-in-human study will measure the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a this drug alone in mCRPC.

NCT07332455 · Official ClinicalTrials.gov record · GlaxoSmithKline

This study will test whether CARTISTEM is safe and works better than debridement (a surgery that cleans out damaged tissue) for people with knee cartilage damage and osteoarthritis. CARTISTEM is a new treatment made of stem cells from donated umbilical cord blood mixed with a gel (hyaluronic acid) that is placed in the damaged area of the knee The main goal is to find out if CARTISTEM® reduces knee pain and improves knee function more than debridement two years after treatment.

NCT07339111 · Official ClinicalTrials.gov record · Medipost, Inc.

This study wants to measure the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

NCT07412704 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment.

NCT07430306 · Official ClinicalTrials.gov record · AstraZeneca

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07430956 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

This study wants to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to dummy treatment (placebo).

NCT07489651 · Official ClinicalTrials.gov record · Reunion Neuroscience Inc

The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.

NCT07589595 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study is a confirmatory, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment randomly assigned clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder. Participants are randomly assigned to receive either active gamma EEG-NFB (real-time feedback of frontal gamma brain activity) or sham EEG-NFB (false pre-recorded feedback), twice weekly for 12 weeks.

NCT07592169 · Official ClinicalTrials.gov record · University of California, San Diego

This study will measure the how well it works and safety of EVO756 against dummy treatment (placebo) in adults with migraine.

NCT07616128 · Official ClinicalTrials.gov record · Evommune, Inc.

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07626411 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

Phase IV, multi-site, open-label, non-randomly assigned study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.

NCT07637942 · Official ClinicalTrials.gov record · International Maternal Pediatric Adolescent AIDS Clinical Trials Group

This study wants to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

NCT07680790 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

To study the effect of anti-inflammatory diet on clinical and biological outcomes in lupus

NCT07713940 · Official ClinicalTrials.gov record · University of California, San Diego